title: Phase II double-blind randomized study of lonidamine and radiotherapy in epidermoid carcinoma of the lung.
abstract: Patients with non metastatic squamous cell lung cancer were treated with radiotherapy (RT) plus lonidamine (LND) or placebo (PLAC), according to a randomized double-blind study design. Treatment with lonidamine 150 mg t.i.d. (27 patients) or placebo (23 patients) started 3 days before RT, lasted up to 7 months. Partial responses were observed in 14 and 6 patients respectively in the LND + RT and PLAC + RT groups. Statistical analysis of the survival curves showed no significant difference between the LND + RT (median 311 days) and PLAC + RT (median 193 days) groups. Stage III patients survived significantly longer (p less than 0.05) when treated with LND + RT (median 318 days) than with PLAC + RT (median 163 days). No synergistic toxic effects between radiation and LND were noted. To confirm these data a new and larger multicentric study is now in progress.
authors.affiliation: Istituto Radiologia Medica, Università, Catania, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Privitera
authors.forename: G B
authors.initials: GB
authors.lastname: Ciottoli
authors.forename: C
authors.initials: C
authors.lastname: Patanè
authors.forename: T
authors.initials: T
authors.lastname: Palmucci
authors.forename: G
authors.initials: G
authors.lastname: Tafuri
authors.forename: F
authors.initials: F
authors.lastname: Marletta
authors.forename: B
authors.initials: B
authors.lastname: De Luca
authors.forename: F
authors.initials: F
authors.lastname: Magnani
authors.forename: M
authors.initials: M
authors.lastname: De Gregorio
authors.forename: S
authors.initials: S
authors.lastname: Greco
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy; D003131:Combined Modality Therapy; D004311:Double-Blind Method; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007191:Indazoles / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy; D008297:Male; D008875:Middle Aged; D011720:Pyrazoles / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D007191:Indazoles; D011720:Pyrazoles; C016371:lonidamine